News
Blade Therapeutics Updates Enrollment Progress for Phase 2 Study of Lead Investigational Therapy BLD-2660 in Treating Patients with COVID-19 Pneumonia
Blade Therapeutics reports its Phase 2 trial of BLD-2660 in COVID-19 pneumonia has enrolled half its 120-patient goal, with full enrollment expected in the third quarter of 2020.